Population screening and cascade testing for carriers of SMA

被引:65
作者
Smith, Melanie [1 ]
Calabro, Vanessa [1 ]
Chong, Belinda [1 ]
Gardiner, Nicole [1 ]
Cowie, Shannon [1 ]
du Sart, Desiree [1 ]
机构
[1] Childrens Hosp, Murdoch Childrens Res Inst, Mol Genet Lab, Victorian Clin Genet Serv, Parkville, Vic 3052, Australia
关键词
spinal muscular atrophy; carrier testing; SMN1; risk assessment; population screening; cascade testing;
D O I
10.1038/sj.ejhg.5201821
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Spinal muscular atrophy (SMA) is one of the most common autosomal-recessive diseases, caused by absence of both copies of the survival motor neuron 1 (SMN1) gene. Identification of SMA carriers has important implications for individuals with a family history and the general population. SMA carriers are completely healthy and most are unaware of their carrier status until they have an affected child. A total of 422 individuals have been studied to identify SMA carriers. This cohort included 117 parents of children homozygously deleted for SMN1 (94% were carriers and 6% had two copies of SMN1; of these individuals, two in seven had the '2+0' genotype, two in seven were normal but had children carrying a de novo deletion and three in seven were unresolved), 158 individuals with a significant family history of SMA (47% had one copy, 49% had two copies and 4% had three copies of SMN1) and 146 individuals with no family history of SMA (90% had two copies, 2% had one copy and 8% had three copies of SMN1). The SMA carrier frequency in the Australian population appears to be 1/49 and the frequency of two-copy SMN1 alleles and de novo deletion mutations are both at least 1.7%. A multimodal approach involving quantitative analysis, linkage analysis and genetic risk assessment (GRA), facilitates the resolution of SMA carrier status in individuals with a family history as well as individuals of the general population, providing couples with better choices in their family planning.
引用
收藏
页码:759 / 766
页数:8
相关论文
共 28 条
[1]   Determination of SMN1 and SMN2 copy number using TaqMan™ technology [J].
Anhuf, D ;
Eggermann, T ;
Rudnik-Schöneborn, S ;
Zerres, K .
HUMAN MUTATION, 2003, 22 (01) :74-78
[2]   When is a deletion not a deletion? When it is converted [J].
Burghes, AHM .
AMERICAN JOURNAL OF HUMAN GENETICS, 1997, 61 (01) :9-15
[3]   Structure and organization of the human survival motor neurone (SMN) gene [J].
Burglen, L ;
Lefebvre, S ;
Clermont, O ;
Burlet, P ;
Viollet, L ;
Cruaud, C ;
Munnich, A ;
Melki, J .
GENOMICS, 1996, 32 (03) :479-482
[4]   Maternal mosaicism for a second mutational event in a type I spinal muscular atrophy family [J].
Campbell, L ;
Daniels, RJ ;
Dubowitz, V ;
Davies, KE .
AMERICAN JOURNAL OF HUMAN GENETICS, 1998, 63 (01) :37-44
[5]   Disruption of an SF2/ASF-dependent exonic splicing enhancer in SMN2 causes spinal muscular atrophy in the absence of SMN1 [J].
Cartegni, L ;
Krainer, AR .
NATURE GENETICS, 2002, 30 (04) :377-384
[6]   Carrier incidence for spinal muscular atrophy in southern Chinese [J].
Chan, V ;
Yip, B ;
Yam, I ;
Au, P ;
Lin, CK ;
Wong, V ;
Chan, TK .
JOURNAL OF NEUROLOGY, 2004, 251 (09) :1089-1093
[7]  
Chen KL, 1999, AM J MED GENET, V85, P463, DOI 10.1002/(SICI)1096-8628(19990827)85:5<463::AID-AJMG6>3.3.CO
[8]  
2-M
[9]   Abnormal SMN1 gene copy number is a susceptibility factor for amyotrophic lateral sclerosis [J].
Corcia, P ;
Mayeux-Portas, V ;
Khoris, J ;
de Toffol, B ;
Autret, A ;
Müh, JP ;
Camu, W ;
Andres, C .
ANNALS OF NEUROLOGY, 2002, 51 (02) :243-246
[10]   Prevalence of SMN1 deletion and duplication in carrier and normal populations:: implication for genetic counselling -: art. no. e39 [J].
Cusin, V ;
Clermont, O ;
Gérard, B ;
Chantereau, D ;
Elion, J .
JOURNAL OF MEDICAL GENETICS, 2003, 40 (04)